Communiqués Lundbeck Nasdaq Copenhagen

Actions

LUN

DK0061804697

Produits pharmaceutiques

PEA

Marché Fermé - Nasdaq Copenhagen 17:20:00 22/09/2026			Varia. 5j.	Varia. 1 janv.
41,75 ^DKK	+1,21 %		+1,21 %	+15,33 %

21/09	UBS relève Lundbeck à l'achat (neutre), objectif de cours 52 couronnes danoises (45)	FW
21/09	Avis d'analystes du jour : les objectifs reculent sur le luxe

Communiqués

21/09	H Lundbeck A/S : Correction - Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties	PU
17/09	Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties	AQ
16/09	Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks	AQ
15/09	Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome	AQ
11/09	The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome	AQ
03/09	Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress	AQ
24/08	European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin	AQ
19/08	Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S	AQ
19/08	Strong growth from Vyepti[®] and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026	AQ
23/07	Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy	AQ
20/07	Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)	AQ
24/06	Tarek Samad appointed EVP, Head of Research & Development at Lundbeck	AQ
24/06	Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026	AQ
14/06	Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026	AQ
10/06	Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026	AQ
04/06	Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress	AQ
03/06	Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments	AQ
26/05	Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine	AQ
19/05	H Lundbeck A/S : Transcript (Transcript)	PU
18/05	Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease	AQ
13/05	H Lundbeck A/S : Investor Presentation (Lundbeck InvestorDeck Q1 2026 FINAL)	PU
12/05	H Lundbeck A/S : Release (Q1 2026 Corporate Release)	PU
12/05	Strong start to 2026: +21% CER revenue growth (+13% CER underlying)	AQ
12/05	Lundbeck raises financial guidance for 2026	AQ
19/04	Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)	AQ